- Oral presentation
- Open access
- Published:
Thioredoxin in Post-Injury Sepsis And Ards
Intensive Care Medicine Experimental volume 3, Article number: A34 (2015)
Introduction
Trauma is one of the leading causes of mortality worldwide, resulting in a great global burden of disability and mortality [1, 2]. Approximately half of all trauma deaths occur during the first hours due to traumatic brain injury or massive bleeding. Later deaths are due to, for example, sepsis or multiple organ failure [3]. Independent risk factors for post-injury sepsis are still somewhat poorly defined. Injury Severity Score (ISS), male gender, age, low Glasgow Coma Scale (GCS) and massive blood transfusion have been suggested as risk factors [4].
Thioredoxin (TRX) is thought to have important anti-oxidant properties but it also functions as an endogenous anti-inflammatory mediator [5]. The link between high plasma levels of TRX and sepsis has been studied previously, although with conflicting evidence [5, 6]. TRX-levels in trauma patients and the possible correlation to secondary complications such as post-injury sepsis and acute respiratory distress syndrome (ARDS) have to our knowledge not been studied previously.
Objectives
To study the relationship between trauma and plasma levels of TRX as well as the possible correlation between post-traumatic plasma-TRX and secondary outcomes such as severe sepsis and ARDS.
Methods
ICU-admitted trauma patients with an expected stay of >3 days (n = 84) were included. Median ISS was 29. Plasma-TRX was analyzed on day 1 and 3. Clinical, physiological and outcome data were retrieved from the trauma and ICU research registries. in addition, we analyzed plasma-TRX in 10 healthy subjects.
Results
A three-fold increase in day 1 plasma-TRX was seen in trauma patients when compared to healthy volunteers (median, IQR 63.9 ng/ml, 39.3-114.6 vs. 22.6 ng/ml, 16.1-25.8 p = 0.0001). High ISS (>25) was associated with high plasma-TRX (median, IQR 72.1 ng/ml, 45.2-129.3 vs. 47.9 ng/ml, 35.0-81.2 p = 0.049).
TRX decreased significantly between day 1 and 3 (median, IQR 63.9 ng/ml, 39.3-114.6 vs. 38.6 ng/ml, 32.4-57.1 p < 0.0001).
There was no significant difference between survivors and non-survivors in plasma-TRX.
Day 1 plasma-TRX levels were significantly increased in patients who later developed severe sepsis compared to those who did not (median, IQR 72.9 ng/ml, 44.8-137.3 vs. 49.8 ng/ml, 39.0-78.3 p = 0.014), no such difference was noted for post-injury ARDS.
Conclusions
TRX levels rise after trauma. Increased plasma-TRX levels are associated with post-injury sepsis. The potential usefulness of TRX as a biomarker in trauma patients needs further evaluation in larger studies.
Grant Acknowledgment
ALF-funding through Stockholm County Council and Karolinska Institutet.
References
GBD 2013. Lancet. 2015, 385 (9963): 117-171.
Patton GC, et al: Lancet. 2009, 374 (9693): 881-892. 10.1016/S0140-6736(09)60741-8.
Soreide K, et al: World J of surg. 2007, 31 (11): 2092-2103. 10.1007/s00268-007-9226-9.
Wafaisade A, et al: Crit C Med. 2011, 39 (4): 621-628. 10.1097/CCM.0b013e318206d3df.
Hofer S, et al: Crit C Med. 2009, 37 (7): 2155-2159. 10.1097/CCM.0b013e31819fff67.
Callister ME, et al: Int C Med. 2007, 33 (2): 364-367. 10.1007/s00134-006-0460-7.
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Eriksson, J., Gidlöf, A., Brattström, O. et al. Thioredoxin in Post-Injury Sepsis And Ards. ICMx 3 (Suppl 1), A34 (2015). https://doi.org/10.1186/2197-425X-3-S1-A34
Published:
DOI: https://doi.org/10.1186/2197-425X-3-S1-A34